Value through Innovation20 December 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

09.09.2013

ERS Congress 2013
Phase III results: Once daily olodaterol* Respimat® provides effective and sustained improvements in lung function in patients with COPD1-3

- For media outside the UK, U.S. and Canada  
09.09.2013

ERS Congress 2013
New Phase III data presented for first time demonstrate: tiotropium* Respimat® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS treatment1

- For media outside the U.S., Canada and UK
09.09.2013

Landmark TIOSPIRTM trial reinforces importance of SPIRIVA® in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD)

- For media outside the UK, US and Canada
03.09.2013

Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases

- For media outside of the US, the UK & Canada only
02.09.2013

Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial, and their respiratory pipeline products in COPD, asthma, IPF and lung cancer at ERS 2013

- For media outside the UK, US and Canada
02.09.2013

New treatment for cats with chronic kidney disease: Boehringer Ingelheim launches Semintra®

26.08.2013

ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations

- For media outside of the US, the UK & Canada only
16.08.2013

Boehringer Ingelheim takes a further step to establish Animal Health business in Asia

15.08.2013

Boehringer Ingelheim announces full patient enrolment for two of its pivotal Phase III interferon-free hepatitis C clinical trials

- For media outside USA, UK and Canada only
15.08.2013

Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet

- For Non-US and Non-UK Media
14.08.2013

First half year 2013: Boehringer Ingelheim remains on growth path

01.08.2013

Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints

- For non U.S. Media Only
31.07.2013

First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes

- For Non-US and Non-UK Media
26.07.2013

Afatinib receives positive CHMP opinion for patients with EGFR mutation positive lung cancer in European Union

- For non U.S. Media Only
17.07.2013

Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding

16.07.2013

Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure

- For media outside of the US, the UK & Canada only
16.07.2013

Healthrageous, United BioSource and Boehringer Ingelheim launch SMART digital diabetes Study

15.07.2013

U.S. FDA approves Gilotrif™ (afatinib)* as first-line treatment for lung cancer patients with EGFR mutations

- For non U.S. Media Only